▁Centre ▁and ▁univers ities ▁in ▁the ▁UK , ▁supported ▁by ▁B BS RC , ▁resulted ▁in ▁the ▁creation ▁of ▁spin - out ▁companies , ▁for ▁example ▁Nov act a ▁B ios ystem s , ▁which ▁has ▁designed ▁the ▁type - b ▁l ant ib i otic - based ▁comp ound ▁N VB 3 0 2 ▁( in ▁phase ▁ 1 ) ▁to ▁treat ▁Clo str id ium ▁diff icile ▁in fe ctions . ▁Possible ▁improvements ▁include ▁clar ification ▁of ▁clin ical ▁trial ▁reg ulations ▁by ▁F DA . ▁Furthermore , ▁appropriate ▁economic ▁in cent ives ▁could ▁persu ade ▁ph arma ce ut ical ▁companies ▁to ▁invest ▁in ▁this ▁ende avor . ▁In ▁the ▁US , ▁the ▁Ant ib i otic ▁Development ▁to ▁Adv ance ▁Pat ient ▁Tre at ment ▁( AD AP T ) ▁Act ▁was ▁introduced ▁with ▁the ▁aim ▁of ▁fast ▁tracking ▁the ▁drug ▁development ▁of ▁ant ib iot ics ▁to ▁combat ▁the ▁growing ▁threat ▁of ▁' super bug s '. ▁Under ▁this ▁Act , ▁F DA ▁can ▁appro ve ▁ant ib iot ics ▁and ▁ant if ung als ▁tre ating ▁life - th re aten ing ▁in fe ctions ▁based ▁on ▁smaller ▁clin ical ▁tri als . ▁The ▁CD C ▁will ▁monitor ▁the ▁use ▁of ▁ant ib iot ics ▁and ▁the ▁emer ging ▁resistance , ▁and ▁publish ▁the ▁data . ▁The ▁F DA ▁ant ib iot ics ▁label ing ▁process , ▁' S us cept ibility ▁Test ▁Inter pret ive ▁C riteria ▁for ▁Micro b ial ▁Organ isms ' ▁or ▁'